Bulk orladeyo pharmaceutical
Ended Awarded Last action
- Contract number
- 36C26025F0070
- Awardee
-
Biocryst Pharmaceuticals Inc. UEI MGXADJ6SCLJ5
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $242,987
Award facts
- Contract value 100% obligated
- $242,986.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Earth City, MO 63045, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$151,867 | |
| Funding Only Action | $9,405 | |
| Original award | $385,448 |
About this award
Biocryst Pharmaceuticals Inc. was awarded a delivery order valued at $242,987 by Veterans Integrated Service Network (VISN) 20 on March 12, 2025, for the supply of bulk Orladeyo pharmaceutical with a 2025 price increase adjustment. The contract utilizes a firm fixed price structure under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and represents an open market award with no set-aside designation. Performance will be completed by March 11, 2026, with the work performed in Earth City, Missouri. This delivery order falls under Biocryst's existing Blanket Purchase Agreement and Federal Supply Schedule contract vehicles with the Department of Veterans Affairs, which streamline procurement of specialized pharmaceutical products across federal healthcare systems.
Orladeyo (berotralstat) is a critical biopharmaceutical used to treat hereditary angioedema, a rare genetic disorder affecting the VA's veteran population. The award reflects Biocryst's established role as a primary supplier of specialized rare disease medications to Veterans Affairs facilities, with consistent contract awards demonstrating the vendor's strategic importance to veteran healthcare services. The Department of Veterans Affairs, a civilian agency within the federal government, utilizes these procurement vehicles to ensure reliable access to specialized medications that support complex medical conditions within the veteran population.
Quick answers
Who was awarded contract 36C26025F0070?
36C26025F0070 was awarded to Biocryst Pharmaceuticals Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on March 12, 2025.
How much is contract 36C26025F0070 worth?
The government has obligated $242,987 on 36C26025F0070.
Is contract 36C26025F0070 an order under another contract?
Yes. 36C26025F0070 is a delivery order under 36F79721D0166, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26025F0070 competed?
The extent of competition for 36C26025F0070 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award